Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Interim Considerations for Clinical Management of Patients

This information is intended to help clinicians and public health officials manage care of patients with acute flaccid myelitis (AFM). It is important to note there are no controlled studies evaluating the efficacy of various treatment regimens for AFM. CDC is currently working with national experts to update and revise these considerations. Healthcare providers should consult with medical experts in neurology and infectious diseases to inform individual clinical decision-making.

Since CDC is still determining potential causes of AFM, we cannot recommend any one treatment. However, CDC received input from an expert group of neurologists, infectious disease experts, pediatricians, immunologists, and public health experts that convened in the fall of 2014 to develop a document with considerations for clinical management of patients with AFM. These considerations are encouraged by this expert group to be used by healthcare providers for clinical management of AFM.

Please note: these considerations are intended to apply to “acute flaccid myelitis,” as defined in the document, and are not intended to be generalized to all forms or etiologies of childhood acute flaccid paralysis, such as Guillain-Barré syndrome, transverse myelitis, or other immune-mediated etiologies. If an alternative diagnosis for the acute paralysis is under consideration, all efforts should be made to explore the alternative diagnosis, and if found, appropriate intervention should be rendered.